Canada tax agency audits Eli Lilly's Canadian unit over transfer-pricing concerns

The Canada Revenue Agency filed a lawsuit in Federal Court seeking documents it says Eli Lilly Canada has withheld, accusing the drugmaker of under-reporting taxable income in 2020. The audit was triggered by profit margins that appeared markedly below those typical for independent firms handling marketing, distribution and related services. According to the filing, most of Lilly’s inventory was obtained from related offshore entities, primarily in Ireland, suggesting possible transfer-pricing manipulation.

Ethan Pigott, a company spokesperson, asserted that Lilly disagrees with the CRA’s assessment and will respond through the court process while remaining open to constructive dialogue. Transfer-pricing rules require Canadian subsidiaries to price intercompany transactions at arm’s-length to ensure appropriate profit reporting, and violations can affect large tax liabilities. Canadian transfer-pricing specialist Matthew Wall highlighted that the pharmaceutical sector is a prime target for such investigations, and the prolonged nature of this audit makes it a high-stakes matter for both parties. The CRA has declined further comment pending the outcome of the legal proceedings.